A multitude of interventional trials are based on the paradigm of typical hypercytokinemia (such as in MAS) in critically ill COVID-19 patients, as a result thereby investigating immunomodulatory therapies such as anti-IL-6 or IFN-γ/IL-1 blockade. This evidence concerns the gene IL1A and COVID-19.